Cipla's US Division Issues Recall for Over 400 Cartons of Nilotinib Anti-Cancer Drug
Synopsis
Cipla's US subsidiary recalls 400+ cartons of Nilotinib, an anti-cancer medication, due to manufacturing issues. The USFDA confirms it's a Class III recall, indicating minimal health risk.
Key Takeaways
Cipla USA recalls over 400 cartons of Nilotinib due to manufacturing defects.
The recall involves specific batches of 150 mg and 200 mg capsules.
Class III recall indicates minimal risk to health.
India is a key supplier of pharmaceuticals to the US market.
Indian drugmakers account for a significant share of US prescriptions.
New Delhi, March 8 (NationPress) A subsidiary of Cipla based in the United States has issued a recall for over 400 cartons of its generic anti-cancer medication due to a manufacturing defect, as reported by the US Food and Drug Administration (USFDA).
In its recent enforcement report, the US health authority stated that Cipla USA, Inc., located in Warren, New Jersey, is recalling specific batches of Nilotinib Capsules available in two dosages: 150 mg and 200 mg.
The recall encompasses 271 cartons from one batch and 164 cartons from another batch of the drug.
The USFDA indicated that the company's decision to recall these lots stemmed from their failure to comply with the necessary specifications for tablets or capsules during production.
The voluntary recall was initiated by Cipla USA on February 18, 2026. The USFDA has categorized this as a Class III recall, which implies that using the product is unlikely to lead to severe health issues or adverse consequences.
Nilotinib is utilized in cancer therapy, functioning by inhibiting the activity of an abnormal protein responsible for the growth and multiplication of cancer cells. By obstructing this protein, the medication aids in slowing or halting the proliferation of cancer cells throughout the body.
India plays a vital role as a supplier of pharmaceuticals to the US market, boasting the highest number of USFDA-compliant manufacturing facilities outside the United States.
Indian pharmaceutical manufacturers are significant contributors to the American healthcare landscape, providing a substantial portion of the medications consumed by patients in the nation.
According to industry statistics, Indian pharmaceutical firms accounted for approximately four out of every ten prescriptions filled in the US in 2022, underscoring their notable presence in the global generics sector.
Additionally, in January of this year, both Sun Pharmaceutical Industries and Cipla recalled various products from the US market due to manufacturing concerns.
The US health regulator had also highlighted that the US division of Mumbai-headquartered Sun Pharma is recalling over 26,000 bottles of a generic treatment for dandruff and skin conditions that induce inflammation and itching.
Point of View
It's vital to highlight the significance of this recall within the broader context of pharmaceutical safety and oversight. Cipla's proactive measures reflect a commitment to quality, although the incident raises concerns regarding manufacturing processes in the industry.
NationPress
2 May 2026
Frequently Asked Questions
What is Nilotinib used for?
Nilotinib is an anti-cancer medication that works by blocking the action of a protein responsible for the growth of cancer cells.
Why was Nilotinib recalled?
The recall was initiated due to a manufacturing defect that caused certain batches to fail to meet tablet or capsule specifications.
What does a Class III recall mean?
A Class III recall indicates that the use of the product is unlikely to cause serious health problems.
How many cartons were recalled?
Cipla recalled a total of over 400 cartons, specifically 271 from one batch and 164 from another.
What other companies have made similar recalls?
In January, Sun Pharmaceutical Industries also recalled products from the US market due to manufacturing issues.
